Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2011, Article ID 746939, 17 pages
http://dx.doi.org/10.1155/2011/746939
Review Article

Targeting the p53 Pathway in Ewing Sarcoma

1Sarcoma Research Group, Discipline of Medicine, University of Adelaide and Hanson Institute, Frome Road, Adelaide, SA 5000, Australia
2Ian Potter Foundation Centre for Cancer Genomics and Predictive Medicine, Peter MacCallum Cancer Centre, East Melbourne, VIC 3002, Australia

Received 4 July 2010; Accepted 28 October 2010

Academic Editor: Alessandro Gronchi

Copyright © 2011 Paul M. Neilsen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. P. Lane, “p53, guardian of the genome,” Nature, vol. 358, no. 6381, pp. 15–16, 1992. View at Publisher · View at Google Scholar · View at Scopus
  2. K. H. Vousden and C. Prives, “Blinded by the light: the growing complexity of p53,” Cell, vol. 137, no. 3, pp. 413–431, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. B. Vogelstein and K. W. Kinzler, “Cancer genes and the pathways they control,” Nature Medicine, vol. 10, no. 8, pp. 789–799, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Vogelstein, D. Lane, and A. J. Levine, “Surfing the p53 network,” Nature, vol. 408, no. 6810, pp. 307–310, 2000. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Kovar, A. Auinger, G. Jug et al., “Narrow spectrum of infrequent p53 mutations and absence of MDM2 amplification in Ewing tumours,” Oncogene, vol. 8, no. 10, pp. 2683–2690, 1993. View at Google Scholar · View at Scopus
  6. H. Komuro, Y. Hayashi, M. Kawamura et al., “Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas,” Cancer Research, vol. 53, no. 21, pp. 5284–5288, 1993. View at Google Scholar · View at Scopus
  7. R. Hamelin, J. Zucman, T. Melot, O. Delatire, and G. Thomas, “p53 Mutations in human tumors with chimeric EWS/FLI-1 genes,” International Journal of Cancer, vol. 57, no. 3, pp. 336–340, 1994. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Patiño-García and L. Sierrasesúmaga, “Analysis of the p16INK4 and TP53 tumor suppressor genes in bone sarcoma pediatric patients,” Cancer Genetics and Cytogenetics, vol. 98, no. 1, pp. 50–55, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. K. Radig, R. Schneider-Stock, I. Röse, U. Mittler, Y. Oda, and A. Roessner, “p53 and ras mutations in Ewing's sarcoma,” Pathology Research and Practice, vol. 194, no. 3, pp. 157–162, 1998. View at Google Scholar · View at Scopus
  10. T. Tsuchiya, K. Sekine, S. Hinohara, T. Namiki, T. Nobori, and Y. Kaneko, “Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma,” Cancer Genetics and Cytogenetics, vol. 120, no. 2, pp. 91–98, 2000. View at Publisher · View at Google Scholar · View at Scopus
  11. J. A. López-Guerrero, A. Pellín, R. Noguera, C. Carda, and A. Llombart-Bosch, “Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors,” Laboratory Investigation, vol. 81, no. 6, pp. 803–814, 2001. View at Google Scholar
  12. H.-Y. Huang, P. B. Illei, Z. Zhao et al., “Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse,” Journal of Clinical Oncology, vol. 23, no. 3, pp. 548–558, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. Y.-K. Park, S. G. Chi, Y. W. Kim, H. R. Park, and K. K. Unni, “P53 mutations in Ewing's sarcoma,” Oncology Reports, vol. 8, no. 3, pp. 533–537, 2001. View at Google Scholar · View at Scopus
  14. K.-L. Schaefer, M. Eisenacher, Y. Braun et al., “Microarray analysis of Ewing's sarcoma family of tumours reveals characteristic gene expression signatures associated with metastasis and resistance to chemotherapy,” European Journal of Cancer, vol. 44, no. 5, pp. 699–709, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Iwamoto, “Diagnosis and treatment of Ewing's sarcoma,” Japanese Journal of Clinical Oncology, vol. 37, no. 2, pp. 79–89, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Riggi and I. Stamenkovic, “The biology of Ewing sarcoma,” Cancer Letters, vol. 254, no. 1, pp. 1–10, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. C. D. M. Fletcher, P. Gustafson, A. Rydholm, H. Willén, and M. Åkerman, “Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification,” Journal of Clinical Oncology, vol. 19, no. 12, pp. 3045–3050, 2001. View at Google Scholar · View at Scopus
  18. S. Pilotti, G. Della Torre, C. Lavarino et al., “Distinct mdm2/p53 expression in patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms,” Journal of Pathology, vol. 181, no. 1, pp. 14–24, 1997. View at Publisher · View at Google Scholar · View at Scopus
  19. A. P. Dei Tos, C. Doglioni, S. Piccinin et al., “Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma,” Journal of Pathology, vol. 181, no. 1, pp. 8–13, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Schneider-Stock, H. Walter, J. Rys, K. Radig, C. Hoang-Vu, and A. Roessner, “No correlation of c-myc overexpression and p53 mutations in liposarcomas,” Virchows Archiv, vol. 433, no. 4, pp. 315–321, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. R. Schneider-Stock, A. Ziegeler, C. Haeckel, D.-S. Franke, J. Rys, and A. Roessner, “Prognostic relevance of p53 alterations and Mib-1 proliferation index in subgroups of primary liposarcomas,” Clinical Cancer Research, vol. 5, no. 10, pp. 2830–2835, 1999. View at Google Scholar · View at Scopus
  22. J. Barretina, B. S. Taylor, S. Banerji et al., “Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy,” Nature Genetics, vol. 42, no. 8, pp. 715–721, 2010. View at Publisher · View at Google Scholar
  23. Y. Oda, H. Yamamoto, T. Takahira et al., “Frequent alteration of p16INK4a/p14ARF and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14ARF expression both correlate with poor prognosis,” Journal of Pathology, vol. 207, no. 4, pp. 410–421, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Toguchida, T. Yamaguchi, B. Ritchie et al., “Mutation spectrum of the p53 gene in bone and soft tissue sarcomas,” Cancer Research, vol. 52, no. 22, pp. 6194–6199, 1992. View at Google Scholar · View at Scopus
  25. E. Latres, M. Drobnjak, D. Pollack et al., “Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas,” American Journal of Pathology, vol. 145, no. 2, pp. 345–355, 1994. View at Google Scholar · View at Scopus
  26. J. S. Castresana, M.-P. Rubio, L. Gomez, A. Kreicbergs, A. Zetterberg, and C. Barrios, “Detection of TP53 gene mutations in human sarcomas,” European Journal of Cancer A, vol. 31, no. 5, pp. 735–738, 1995. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Nawa, Y. Miyoshi, H. Yoshikawa, T. Ochi, and Y. Nakamura, “Frequent loss of expression or aberrant alternative splicing of P2XM, a p53-inducible gene, in soft-tissue tumours,” British Journal of Cancer, vol. 80, no. 8, pp. 1185–1189, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. P. Das, D. Kotilingam, B. Korchin et al., “High prevalence of p53 exon 4 mutations in soft tissue sarcoma,” Cancer, vol. 109, no. 11, pp. 2323–2333, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. C. A. Felix, C. C. Kappel, T. Mitsudomi et al., “Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma,” Cancer Research, vol. 52, no. 8, pp. 2243–2247, 1992. View at Google Scholar · View at Scopus
  30. T. Kusafuka, M. Fukuzawa, T. Oue, Y. Komoto, A. Yoneda, and A. Okada, “Mutation analysis of p53 gene in childhood malignant solid tumors,” Journal of Pediatric Surgery, vol. 32, no. 8, pp. 1175–1180, 1997. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Mora, A. M. Dobrenis, J. B. Bussel, and A. Aledo, “p53 mutation and MDM2 amplification frequency pediatric rhabdomyosarcoma tumors and cell lines,” Medical and Pediatric Oncology, vol. 35, no. 2, pp. 96–103, 2000. View at Publisher · View at Google Scholar
  32. Y. Takahashi, Y. Oda, K.-I. Kawaguchi et al., “Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma,” Modern Pathology, vol. 17, no. 6, pp. 660–669, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. R. Schneider-Stock, K. Radig, Y. Oda et al., “p53 gene mutations in soft-tissue sarcomas—correlations with p53 immunohistochemistry and DNA ploidy,” Journal of Cancer Research and Clinical Oncology, vol. 123, no. 4, pp. 211–218, 1997. View at Publisher · View at Google Scholar · View at Scopus
  34. A. P. Dei Tos, C. Doglioni, G. Muffato et al., “Synovial sarcoma exhibits deregulation of the G1-S cell cycle checkpoint and of the apoptotic pathway,” Modern Pathology, vol. 12, p. 10A, 1999. View at Google Scholar
  35. R. Schneider-Stock, D. Onnasch, C. Haeckel, W. Mellin, D.-S. Franke, and A. Roessner, “Prognostic significance of p53 gene mutations and p53 protein expression in synovial sarcomas,” Virchows Archiv, vol. 435, no. 4, pp. 407–412, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Oda, A. Sakamoto, T. Satio, S. Kawauchi, Y. Iwamoto, and M. Tsuneyoshi, “Molecular abnormalities of p53, MDM2, and H-ras synovial sarcoma,” Modern Pathology, vol. 13, no. 9, pp. 994–1004, 2000. View at Google Scholar · View at Scopus
  37. A. Andreassen, T. Oyjord, E. Hovig et al., “p53 Abnormalities in different subtypes of human sarcomas,” Cancer Research, vol. 53, no. 3, pp. 468–471, 1993. View at Google Scholar · View at Scopus
  38. F. S. Leach, T. Tokino, P. Meltzer et al., “p53 Mutation and MDM2 amplification in human soft tissue sarcomas,” Cancer Research, vol. 53, no. 10, pp. 2231–2234, 1993. View at Google Scholar · View at Scopus
  39. H. Patterson, S. Gill, C. Fisher et al., “Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas,” British Journal of Cancer, vol. 69, no. 6, pp. 1052–1058, 1994. View at Google Scholar · View at Scopus
  40. C. W. Miller, A. Aslo, A. Won, M. Tan, B. Lampkin, and H. P. Koeffler, “Alterations of the p53, Rb and MDM2 genes in osteosarcoma,” Journal of Cancer Research and Clinical Oncology, vol. 122, no. 9, pp. 559–565, 1996. View at Google Scholar · View at Scopus
  41. K. L. Hall, M. G. Teneriello, R. R. Taylor et al., “Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas,” Gynecologic Oncology, vol. 65, no. 2, pp. 330–335, 1997. View at Publisher · View at Google Scholar · View at Scopus
  42. Y.-L. Zhai, T. Nikaido, T. Toki, A. Shiozawa, A. Orii, and S. Fujii, “Prognostic significance of bcl-2 expression in leiomyosarcoma of the uterus,” British Journal of Cancer, vol. 80, no. 10, pp. 1658–1664, 1999. View at Publisher · View at Google Scholar · View at Scopus
  43. K. Miyajima, S. Tamiya, Y. Oda et al., “Relative quantitation of p53 and MDM2 gene expression in leiomyosarcoma; real-time semi-quantitative reverse transcription-polymerase chain reaction,” Cancer Letters, vol. 164, no. 2, pp. 177–188, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. N. Gokgoz, J. S. Wunder, S. Mousses, S. Eskandarian, R. S. Bell, and I. L. Andrulis, “Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma,” Cancer, vol. 92, no. 8, pp. 2181–2189, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. M. Overholtzer, P. H. Rao, R. Favis et al., “The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 20, pp. 11547–11552, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Petitjean, M. I. W. Achatz, A. L. Borresen-Dale, P. Hainaut, and M. Olivier, “TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes,” Oncogene, vol. 26, no. 15, pp. 2157–2165, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. D. P. Lane, “p53 and human cancers,” British Medical Bulletin, vol. 50, no. 3, pp. 582–599, 1994. View at Google Scholar · View at Scopus
  48. J. A. Lopez-Guerrero, I. Machado, K. Scotlandi et al., “Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's Sarcoma Family of Tumors,” International Journal of Cancer. In press.
  49. L. M. Mulligan, G. J. Matlashewski, H. J. Scrable, and W. K. Cavenee, “Mechanisms of p53 loss in human sarcomas,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 15, pp. 5863–5867, 1990. View at Publisher · View at Google Scholar · View at Scopus
  50. C. W. Miller, A. Aslo, C. Tsay et al., “Frequency and structure of p53 rearrangements in human osteosarcoma,” Cancer Research, vol. 50, no. 24, pp. 7950–7954, 1990. View at Google Scholar · View at Scopus
  51. J. Momand, D. Jung, S. Wilczynski, and J. Niland, “The MDM2 gene amplification database,” Nucleic Acids Research, vol. 26, no. 15, pp. 3453–3459, 1998. View at Publisher · View at Google Scholar · View at Scopus
  52. X. Wu, J. H. Bayle, D. Olson, and A. J. Levine, “The p53-mdm-2 autoregulatory feedback loop,” Genes and Development, vol. 7, no. 7, pp. 1126–1132, 1993. View at Google Scholar · View at Scopus
  53. Y. Haupt, R. Maya, A. Kazaz, and M. Oren, “Mdm2 promotes the rapid degradation of p53,” Nature, vol. 387, no. 6630, pp. 296–299, 1997. View at Publisher · View at Google Scholar · View at Scopus
  54. M. H. G. Kubbutat, S. N. Jones, and K. H. Vousden, “Regulation of p53 stability by Mdm2,” Nature, vol. 387, no. 6630, pp. 299–303, 1997. View at Publisher · View at Google Scholar · View at Scopus
  55. F. Pedeutour, A. Forus, J.-M. Coindre et al., “Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors,” Genes Chromosomes and Cancer, vol. 24, no. 1, pp. 30–41, 1999. View at Publisher · View at Google Scholar · View at Scopus
  56. F. J. Stott, S. Bates, M. C. James et al., “The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2,” The EMBO Journal, vol. 17, no. 17, pp. 5001–5014, 1998. View at Publisher · View at Google Scholar · View at Scopus
  57. J. Pomerantz, N. Schreiber-Agus, N. J. Liégeois et al., “The Ink4a tumor suppressor gene product, p19(Arf), interacts with MDM2 and neutralizes MDM2's inhibition of p53,” Cell, vol. 92, no. 6, pp. 713–723, 1998. View at Publisher · View at Google Scholar · View at Scopus
  58. M. Ladanyi, R. Lewis, S. C. Jhanwar, W. Gerald, A. G. Huvos, and J. H. Healey, “MDM2 and CDK4 gene amplification in Ewing's sarcoma,” Journal of Pathology, vol. 175, no. 2, pp. 211–217, 1995. View at Publisher · View at Google Scholar · View at Scopus
  59. G. Wei, C. R. Antonescu, E. De Alava et al., “Prognostic impact of INK4A deletion in Ewing sarcoma,” Cancer, vol. 89, no. 4, pp. 793–799, 2000. View at Publisher · View at Google Scholar · View at Scopus
  60. S. C. Brownhill, C. Taylor, and S. A. Burchill, “Chromosome 9p21 gene copy number and prognostic significance of p16 in ESFT,” British Journal of Cancer, vol. 96, no. 12, pp. 1914–1923, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. F. Bartel, J. Schulz, A. Böhnke et al., “Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis,” International Journal of Cancer, vol. 117, no. 3, pp. 469–475, 2005. View at Publisher · View at Google Scholar · View at Scopus
  62. D. Danovi, E. Meulmeester, D. Pasini et al., “Amplification of Mdmx (or Mdm4) directly contributes to tumor formation by inhibiting p53 tumor suppressor activity,” Molecular and Cellular Biology, vol. 24, no. 13, pp. 5835–5843, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Shvarts, M. Bazuine, P. Dekker et al., “Isolation and identification of the human homolog of a new p53-binding protein, Mdmx,” Genomics, vol. 43, no. 1, pp. 34–42, 1997. View at Publisher · View at Google Scholar · View at Scopus
  64. N. A. Laurie, S. L. Donovan, C.-S. Shih et al., “Inactivation of the p53 pathway in retinoblastoma,” Nature, vol. 444, no. 7115, pp. 61–66, 2006. View at Publisher · View at Google Scholar · View at Scopus
  65. P. A.J. Muller, P. T. Caswell, B. Doyle et al., “Mutant p53 drives invasion by promoting integrin recycling,” Cell, vol. 139, no. 7, pp. 1327–1341, 2009. View at Publisher · View at Google Scholar
  66. H. Kovar, S. Pospisilova, G. Jug, D. Printz, and H. Gadner, “Response of Ewing tumor cells to forced and activated p53 expression,” Oncogene, vol. 22, no. 21, pp. 3193–3204, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. M. Ladanyi, “EWS-FLI1 and Ewing's sarcoma: recent molecular data and new insights,” Cancer Biology & Therapy, vol. 1, no. 4, pp. 330–336, 2002. View at Google Scholar · View at Scopus
  68. A. Abudu, D. C. Mangham, G. M. Reynolds et al., “Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis,” British Journal of Cancer, vol. 79, no. 7-8, pp. 1185–1189, 1999. View at Publisher · View at Google Scholar · View at Scopus
  69. E. de Alava, C. R. Antonescu, A. Panizo et al., “Prognostic impact of P53 status in Ewing sarcoma,” Cancer, vol. 89, no. 4, pp. 783–792, 2000. View at Publisher · View at Google Scholar · View at Scopus
  70. T. Ozaki, M. Paulussen, C. Poremba et al., “Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors,” Genes Chromosomes and Cancer, vol. 32, no. 2, pp. 164–171, 2001. View at Publisher · View at Google Scholar
  71. S. Savola, A. Klami, A. Tripathi et al., “Combined use of expression and CGH arrays pinpoints novel candidate genes in Ewing sarcoma family of tumors,” BMC Cancer, vol. 9, article 17, 2009. View at Publisher · View at Google Scholar · View at Scopus
  72. P. M. Neilsen, K. M. Cheney, C.-W. Li et al., “Identification of ANKRD11 as a p53 coactivator,” Journal of Cell Science, vol. 121, no. 21, pp. 3541–3552, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. O. Delattre, J. Zucman, B. Plougastel et al., “Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours,” Nature, vol. 359, no. 6391, pp. 162–165, 1992. View at Publisher · View at Google Scholar · View at Scopus
  74. J. Zucman, T. Melot, C. Desmaze et al., “Combinatorial generation of variable fusion proteins in the Ewing family of tumours,” The EMBO Journal, vol. 12, no. 12, pp. 4481–4487, 1993. View at Google Scholar · View at Scopus
  75. H. Kovar, D. N. T. Aryee, G. Jug et al., “EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro,” Cell Growth and Differentiation, vol. 7, no. 4, pp. 429–437, 1996. View at Google Scholar · View at Scopus
  76. M. Ouchida, T. Ohno, Y. Fujimura, V. N. Rao, and E. S. P. Reddy, “Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts,” Oncogene, vol. 11, no. 6, pp. 1049–1054, 1995. View at Google Scholar · View at Scopus
  77. K. Tanaka, T. Iwakuma, K. Harimaya, H. Sato, and Y. Iwamoto, “EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells,” The Journal of Clinical Investigation, vol. 99, no. 2, pp. 239–247, 1997. View at Google Scholar · View at Scopus
  78. J. A. Toretsky, Y. Connell, L. Neckers, and N. K. Bhat, “Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides,” Journal of Neuro-Oncology, vol. 31, no. 1-2, pp. 9–16, 1997. View at Google Scholar · View at Scopus
  79. J. Ban, I. M. Bennani-Baiti, M. Kauer et al., “EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma,” Cancer Research, vol. 68, no. 17, pp. 7100–7109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  80. Y. Li, K. Tanaka, X. Fan et al., “Inhibition of the transcriptional function of p53 by EWS-Fli1 chimeric protein in Ewing Family Tumors,” Cancer Letters, vol. 294, no. 1, pp. 57–65, 2010. View at Publisher · View at Google Scholar
  81. P. H. B. Sorensen, S. L. Lessnick, D. Lopez-Terrada, X. F. Liu, T. J. Triche, and C. T. Denny, “A second Ewing's sarcoma translocation, t(21;22), fuses the EWS gene to another ETS-family transcription factor, ERG,” Nature Genetics, vol. 6, no. 2, pp. 146–151, 1994. View at Publisher · View at Google Scholar · View at Scopus
  82. I.-S. Jeon, J. N. Davis, B. S. Braun et al., “A variant Ewing's sarcoma translocation (7;22) fuses the EWS gene to the ETS gene ETV1,” Oncogene, vol. 10, no. 6, pp. 1229–1234, 1995. View at Google Scholar · View at Scopus
  83. Y. Kaneko, K. Yoshida, M. Handa et al., “Fusion of an ETS-family gene, EIAF, to EWS by t(17;22)(q12;q12) chromosome translocation in an undifferentiated sarcoma of infancy,” Genes Chromosomes and Cancer, vol. 15, no. 2, pp. 115–121, 1996. View at Google Scholar · View at Scopus
  84. M. Peter, J. Couturier, H. Pacquement et al., “A new member of the ETS family fused to EWS in Ewing tumors,” Oncogene, vol. 14, no. 10, pp. 1159–1164, 1997. View at Google Scholar · View at Scopus
  85. A. Martini, R. La Starza, H. Janssen et al., “Recurrent rearrangement of the Ewing's sarcoma gene, EWSR1, or its homologue, TAF15, with the transcription factor CIZ/NMP4 in acute leukemia,” Cancer Research, vol. 62, no. 19, pp. 5408–5412, 2002. View at Google Scholar · View at Scopus
  86. K. H. Hallor, F. Mertens, Y. Jin et al., “Fusion of the EWSR1 and ATF1 genes without expression of the MITF-M transcript in angiomatoid fibrous histiocytoma,” Genes Chromosomes and Cancer, vol. 44, no. 1, pp. 97–102, 2005. View at Publisher · View at Google Scholar · View at Scopus
  87. S. Rossi, K. Szuhai, M. Ijszenga et al., “EWSR1-CREB1 and EWSR1-ATF1 fusion genes in angiomatoid fibrous histiocytoma,” Clinical Cancer Research, vol. 13, no. 24, pp. 7322–7328, 2007. View at Publisher · View at Google Scholar · View at Scopus
  88. J. Zucman, O. Delattre, C. Desmaze et al., “EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts,” Nature Genetics, vol. 4, no. 4, pp. 341–345, 1993. View at Publisher · View at Google Scholar · View at Scopus
  89. C. R. Antonescu, K. Nafa, N. H. Segal, P. Dal Cin, and M. Ladanyi, “EWS-CREB1: a recurrent variant fusion in clear cell sarcoma-association with gastrointestinal location and absence of melanocytic differentiation,” Clinical Cancer Research, vol. 12, no. 18, pp. 5356–5362, 2006. View at Publisher · View at Google Scholar · View at Scopus
  90. M. Ladanyi and W. Gerald, “Fusion of the EWS and WT1 genes in the desmoplastic small round cell tumor,” Cancer Research, vol. 54, no. 11, pp. 2837–2840, 1994. View at Google Scholar · View at Scopus
  91. J. Clark, H. Benjamin, S. Gill et al., “Fusion of the EWS gene to CHN, a member of the steroid/thyroid receptor gene superfamily, in a human myxoid chondrosarcoma,” Oncogene, vol. 12, no. 2, pp. 229–235, 1996. View at Google Scholar · View at Scopus
  92. C. Orndal, B. Carlen, M. Akerman et al., “Chromosomal abnormaity t(9;22)(q22;q12) in an extraskeletal myxoid chondrosarcoma characterized by fine needle aspiration cytology, electron microscopy, immunohistochemistry and DNA flow cytometry,” Cytopathology, vol. 2, no. 5, pp. 261–270, 1991. View at Google Scholar · View at Scopus
  93. I. Panagopoulos, M. Höglund, F. Mertens, N. Mandahl, F. Mitelman, and P. Åman, “Fusion of the EWS and CHOP genes in myxoid liposarcoma,” Oncogene, vol. 12, no. 3, pp. 489–494, 1996. View at Google Scholar · View at Scopus
  94. C. Turc-Carel, P. Dal Cin, J. Limon, F. Li, and A. A. Sandberg, “Translocation X;18 in synovial sarcoma,” Cancer Genetics and Cytogenetics, vol. 23, no. 1, p. 93, 1986. View at Google Scholar · View at Scopus
  95. P. D'Arcy, W. Maruwge, B. A. Ryan, and B. Brodin, “The oncoprotein SS18-SSX1 promotes p53 ubiquitination and degradation by enhancing HDM2 stability,” Molecular Cancer Research, vol. 6, no. 1, pp. 127–138, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. S. L. Lessnick, C. S. Dacwag, and T. R. Golub, “The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts,” Cancer Cell, vol. 1, no. 4, pp. 393–401, 2002. View at Publisher · View at Google Scholar · View at Scopus
  97. B. Deneen and C. T. Denny, “Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation,” Oncogene, vol. 20, no. 46, pp. 6731–6741, 2001. View at Publisher · View at Google Scholar · View at Scopus
  98. M. Braig and C. A. Schmitt, “Oncogene-induced senescence: putting the brakes on tumor development,” Cancer Research, vol. 66, no. 6, pp. 2881–2884, 2006. View at Publisher · View at Google Scholar · View at Scopus
  99. A. Sala, I. Casella, L. Grasso et al., “Apoptotic response to oncogenic stimuli: cooperative and antagonistic interactions between c-myb and the growth suppressor p53,” Cancer Research, vol. 56, no. 9, pp. 1991–1996, 1996. View at Google Scholar · View at Scopus
  100. M. Kauer, J. Ban, R. Kofler et al., “A molecular function map of Ewing's sarcoma,” PLoS ONE, vol. 4, no. 4, Article ID e5415, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. Y. Castillero-Trejo, S. Eliazer, L. Xiang, J. A. Richardson, and R. L. Ilaria Jr., “Expression of the EWS/FLI-1 oncogene in murine primary bone-derived cells results in EWS/FLI-1-dependent, Ewing sarcoma-like tumors,” Cancer Research, vol. 65, no. 19, pp. 8698–8705, 2005. View at Publisher · View at Google Scholar · View at Scopus
  102. N. Riggi, L. Cironi, P. Provero et al., “Development of Ewing's sarcoma from primary bone marrow-derived mesenchymal progenitor cells,” Cancer Research, vol. 65, no. 24, pp. 11459–11468, 2005. View at Publisher · View at Google Scholar · View at Scopus
  103. N. Riggi, M.-L. Suvà, D. Suvà et al., “EWS-FLI-1 expression triggers a ewing's sarcoma initiation program in primary human mesenchymal stem cells,” Cancer Research, vol. 68, no. 7, pp. 2176–2185, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. P. P. Lin, M. K. Pandey, F. Jin et al., “EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model,” Cancer Research, vol. 68, no. 21, pp. 8968–8975, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. R. Baserga, “The insulin-like growth factor I receptor: a key to tumor growth?” Cancer Research, vol. 55, no. 2, pp. 249–252, 1995. View at Google Scholar · View at Scopus
  106. R. Baserga, M. Resnicoff, and M. Dews, “The IGF-I receptor and cancer,” Endocrine, vol. 7, no. 1, pp. 99–102, 1997. View at Google Scholar · View at Scopus
  107. H. Werner and D. L. Roith, “The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis,” Critical Reviews in Oncogenesis, vol. 8, no. 1, pp. 71–92, 1997. View at Google Scholar · View at Scopus
  108. A. Prieur, F. Tirode, P. Cohen, and O. Delattre, “EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3,” Molecular and Cellular Biology, vol. 24, no. 16, pp. 7275–7283, 2004. View at Publisher · View at Google Scholar · View at Scopus
  109. D. M. Thomas and A. J. Wagner, “Specific targets in sarcoma and developmental therapeutics,” JNCCN Journal of the National Comprehensive Cancer Network, vol. 8, no. 6, pp. 677–685, 2010. View at Google Scholar
  110. A. W. Tolcher, J. Sarantopoulos, A. Patnaik et al., “Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5800–5807, 2009. View at Publisher · View at Google Scholar
  111. D. Olmos, S. Postel-Vinay, L. R. Molife et al., “Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study,” The Lancet Oncology, vol. 11, no. 2, pp. 129–135, 2010. View at Publisher · View at Google Scholar
  112. H. Werner, E. Karnieli, F. J. Rauscher III, and D. LeRoith, “Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 16, pp. 8318–8323, 1996. View at Publisher · View at Google Scholar · View at Scopus
  113. L. Buckbinder, R. Talbott, S. Velasco-Miguel et al., “Induction of the growth inhibitor IGF-binding protein 3 by p53,” Nature, vol. 377, no. 6550, pp. 646–649, 1995. View at Google Scholar · View at Scopus
  114. P. Froment, J. Dupont, and J. Christophe-Marine, “Mdm2 exerts pro-apoptotic activities by antagonizing insulin-like growth factor-I-mediated survival,” Cell Cycle, vol. 7, no. 19, pp. 3098–3103, 2008. View at Google Scholar · View at Scopus
  115. L. Girnita, A. Girnita, and O. Larsson, “Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8247–8252, 2003. View at Publisher · View at Google Scholar · View at Scopus
  116. L. Xiong, F. Kou, Y. Yang, and J. Wu, “A novel role for IGF-1R in p53-mediated apoptosis through translational modulation of the p53-Mdm2 feedback loop,” Journal of Cell Biology, vol. 178, no. 6, pp. 995–1007, 2007. View at Publisher · View at Google Scholar · View at Scopus
  117. L. T. Vassilev, B. T. Vu, B. Graves et al., “In vivo activation of the p53 pathway by small-molecule antagonists of MDM2,” Science, vol. 303, no. 5659, pp. 844–848, 2004. View at Publisher · View at Google Scholar · View at Scopus
  118. C. R. Müller, E. B. Paulsen, P. Noordhuis, F. Pedeutour, G. Sæter, and O. Myklebost, “Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A,” International Journal of Cancer, vol. 121, no. 1, pp. 199–205, 2007. View at Publisher · View at Google Scholar · View at Scopus
  119. M. Miyachi, N. Kakazu, S. Yagyu et al., “Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells,” Clinical Cancer Research, vol. 15, no. 12, pp. 4077–4084, 2009. View at Publisher · View at Google Scholar · View at Scopus
  120. P. D'Arcy, B. A. Ryan, and B. Brodin, “Reactivation of p53 function in synovial sarcoma cells by inhibition of p53-HDM2 interaction,” Cancer Letters, vol. 275, no. 2, pp. 285–292, 2009. View at Publisher · View at Google Scholar · View at Scopus
  121. T. Van Maerken, F. Speleman, J. Vermeulen et al., “Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma,” Cancer Research, vol. 66, no. 19, pp. 9646–9655, 2006. View at Publisher · View at Google Scholar · View at Scopus
  122. L. Coll-Mulet, D. Iglesias-Serret, A. F. Santidrián et al., “MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells,” Blood, vol. 107, no. 10, pp. 4109–4114, 2006. View at Publisher · View at Google Scholar · View at Scopus
  123. L. Gu, N. Zhu, H. W. Findley, and M. Zhou, “MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2,” Leukemia, vol. 22, no. 4, pp. 730–739, 2008. View at Publisher · View at Google Scholar · View at Scopus
  124. K. Kojima, M. Konopleva, I. J. Samudio et al., “MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy,” Blood, vol. 106, no. 9, pp. 3150–3159, 2005. View at Publisher · View at Google Scholar · View at Scopus
  125. K. I. Pishas, F. Al-Ejeh, I. Zinonos et al., “Nutlin-3a is a potential therapeutic for Ewing Sarcoma,” Clinical Cancer Research. In press.
  126. G. Rosen, N. Wollner, and C. Tan, “Disease free survival in children with Ewing's sarcoma treated with radiation therapy and adjuvant four drug sequential chemotherapy,” Cancer, vol. 33, no. 2, pp. 384–393, 1974. View at Google Scholar
  127. H. E. Grier, M. D. Krailo, N. J. Tarbell et al., “Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone,” New England Journal of Medicine, vol. 348, no. 8, pp. 694–701, 2003. View at Publisher · View at Google Scholar · View at Scopus
  128. S. Shangary, D. Qin, D. McEachern et al., “Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 10, pp. 3933–3938, 2008. View at Publisher · View at Google Scholar · View at Scopus
  129. N. Issaeva, P. Bozko, M. Enge et al., “Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors,” Nature Medicine, vol. 10, no. 12, pp. 1321–1328, 2004. View at Publisher · View at Google Scholar · View at Scopus
  130. S. Lain, J. J. Hollick, J. Campbell et al., “Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator,” Cancer Cell, vol. 13, no. 5, pp. 454–463, 2008. View at Publisher · View at Google Scholar · View at Scopus
  131. E. Langley, M. Pearson, M. Faretta et al., “Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence,” The EMBO Journal, vol. 21, no. 10, pp. 2383–2396, 2002. View at Publisher · View at Google Scholar · View at Scopus
  132. A. Vaquero, M. B. Scher, H. L. Dong et al., “SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis,” Genes and Development, vol. 20, no. 10, pp. 1256–1261, 2006. View at Publisher · View at Google Scholar · View at Scopus
  133. H. Vaziri, S. K. Dessain, E. N. Eaton et al., “hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase,” Cell, vol. 107, no. 2, pp. 149–159, 2001. View at Publisher · View at Google Scholar · View at Scopus
  134. Y. Tang, J. Luo, W. Zhang, and W. Gu, “TTip60-dependent acetylation of p53 modulates the decision between cell-cycle arrest and apoptosis,” Molecular Cell, vol. 24, no. 6, pp. 827–839, 2006. View at Publisher · View at Google Scholar
  135. Y. Tang, W. Zhao, Y. Chen, Y. Zhao, and W. Gu, “Acetylation is indispensable for p53 activation,” Cell, vol. 133, no. 4, pp. 612–626, 2008. View at Publisher · View at Google Scholar
  136. M. L. Choong, H. Yang, M. A. Lee, and D. P. Lane, “Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy,” Cell Cycle, vol. 8, no. 17, pp. 2810–2818, 2009. View at Google Scholar
  137. H. M. Sobell, “Actinomycin and DNA transcription,” Proceedings of the National Academy of Sciences of the United States of America, vol. 82, pp. 5328–5331, 1985. View at Google Scholar
  138. G. J. Veal, M. Cole, J. Errington et al., “Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group study,” Clinical Cancer Research, vol. 11, no. 16, pp. 5893–5899, 2005. View at Publisher · View at Google Scholar
  139. J. T. Mondick, L. Gibiansky, M. R. Gastonguay et al., “Population pharmacokinetic investigation of actinomycin-D in children and young adults,” Journal of Clinical Pharmacology, vol. 48, no. 1, pp. 35–42, 2008. View at Publisher · View at Google Scholar